JP2021518111A5 - - Google Patents
Info
- Publication number
- JP2021518111A5 JP2021518111A5 JP2020549002A JP2020549002A JP2021518111A5 JP 2021518111 A5 JP2021518111 A5 JP 2021518111A5 JP 2020549002 A JP2020549002 A JP 2020549002A JP 2020549002 A JP2020549002 A JP 2020549002A JP 2021518111 A5 JP2021518111 A5 JP 2021518111A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- nucleic acid
- cell
- amino acid
- cancer
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023114641A JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643139P | 2018-03-14 | 2018-03-14 | |
| US62/643,139 | 2018-03-14 | ||
| PCT/US2019/021833 WO2019178085A1 (en) | 2018-03-14 | 2019-03-12 | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114641A Division JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518111A JP2021518111A (ja) | 2021-08-02 |
| JPWO2019178085A5 JPWO2019178085A5 (https=) | 2022-03-18 |
| JP2021518111A5 true JP2021518111A5 (https=) | 2022-03-18 |
| JP7314161B2 JP7314161B2 (ja) | 2023-07-25 |
Family
ID=67907266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549002A Active JP7314161B2 (ja) | 2018-03-14 | 2019-03-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
| JP2023114641A Active JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114641A Active JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12606603B2 (https=) |
| EP (2) | EP4491718A3 (https=) |
| JP (2) | JP7314161B2 (https=) |
| KR (2) | KR20260021083A (https=) |
| CN (1) | CN112088165A (https=) |
| AU (2) | AU2019234580B2 (https=) |
| BR (1) | BR112020018534A2 (https=) |
| CA (1) | CA3093791A1 (https=) |
| EA (1) | EA202091984A1 (https=) |
| IL (1) | IL277268A (https=) |
| MX (2) | MX2020009464A (https=) |
| SG (1) | SG11202008926RA (https=) |
| WO (1) | WO2019178085A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019178078A1 (en) | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy |
| CN119654345A (zh) * | 2022-08-25 | 2025-03-18 | 南京传奇生物科技有限公司 | 靶向白介素13受体亚基α2的嵌合抗原受体及其使用方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| EP2220117A2 (en) | 2007-11-30 | 2010-08-25 | Kalobios Pharmaceuticals, Inc. | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| DK2496698T3 (en) * | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| CN104936621A (zh) | 2012-11-07 | 2015-09-23 | 辉瑞公司 | 抗IL-13受体α2抗体和抗体-药物缀合物 |
| JP6345688B2 (ja) | 2012-12-05 | 2018-06-20 | ソラ・バイオサイエンシズ・エルエルシー | タンパク質発現増強ポリペプチド |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| CN107002084B (zh) * | 2014-09-19 | 2021-09-10 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
| JP7264592B2 (ja) | 2015-01-26 | 2023-04-25 | ザ ユニバーシティー オブ シカゴ | ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用 |
| EP3324984A4 (en) | 2015-07-21 | 2019-03-27 | City of Hope | T-LYMPHOCYTES FOR THE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS |
| JP6905163B2 (ja) * | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| ES2879700T3 (es) * | 2016-02-05 | 2021-11-22 | Hope City | Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central |
| WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| MA45779A (fr) * | 2016-07-29 | 2019-06-05 | Juno Therapeutics Inc | Polypeptides immunomdulateurs et compositions et procédés associés |
| JP2019530440A (ja) * | 2016-09-02 | 2019-10-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物 |
| WO2018156711A1 (en) | 2017-02-22 | 2018-08-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Il13ra2-binding chimeric antigen receptors |
| WO2019178078A1 (en) | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy |
-
2019
- 2019-03-12 SG SG11202008926RA patent/SG11202008926RA/en unknown
- 2019-03-12 BR BR112020018534-5A patent/BR112020018534A2/pt not_active Application Discontinuation
- 2019-03-12 WO PCT/US2019/021833 patent/WO2019178085A1/en not_active Ceased
- 2019-03-12 KR KR1020267001996A patent/KR20260021083A/ko active Pending
- 2019-03-12 KR KR1020207028968A patent/KR102917671B1/ko active Active
- 2019-03-12 EA EA202091984A patent/EA202091984A1/ru unknown
- 2019-03-12 EP EP24214241.2A patent/EP4491718A3/en active Pending
- 2019-03-12 JP JP2020549002A patent/JP7314161B2/ja active Active
- 2019-03-12 US US16/979,475 patent/US12606603B2/en active Active
- 2019-03-12 EP EP19767433.6A patent/EP3765487A4/en not_active Withdrawn
- 2019-03-12 AU AU2019234580A patent/AU2019234580B2/en active Active
- 2019-03-12 CA CA3093791A patent/CA3093791A1/en active Pending
- 2019-03-12 MX MX2020009464A patent/MX2020009464A/es unknown
- 2019-03-12 CN CN201980030021.9A patent/CN112088165A/zh active Pending
-
2020
- 2020-09-10 MX MX2025010440A patent/MX2025010440A/es unknown
- 2020-09-10 IL IL277268A patent/IL277268A/en unknown
-
2023
- 2023-07-12 JP JP2023114641A patent/JP7696958B2/ja active Active
-
2024
- 2024-04-24 AU AU2024202681A patent/AU2024202681A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518108A5 (https=) | ||
| US20250043013A1 (en) | Nucleic acids encoding il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy | |
| JP6543626B2 (ja) | 多部分シグナル伝達タンパク質およびその使用 | |
| EP3445847B1 (en) | Immunomodulatory il2r fusion proteins and uses thereof | |
| US20170292118A1 (en) | Method for modulating car-induced immune cells activity | |
| JPWO2019178078A5 (https=) | ||
| JP7696958B2 (ja) | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 | |
| JP2021518111A5 (https=) | ||
| JPWO2019178085A5 (https=) | ||
| EP4382119A1 (en) | A kit for use in the treatment of hematological cancer | |
| JP2025540251A (ja) | 血液癌の治療において使用するためのキット | |
| WO2023102109A1 (en) | Ex vivo cytokine priming strategies for preparing activated cd26-high immune cells and uses in cancer therapies | |
| JP2023529443A (ja) | 抗ｃｄ１７１キメラ抗原受容体 |